$CAI

Caris Life Sciences, Inc.

Caris Life Sciences develops and commercializes molecular profiling and data analysis solutions for patients, physicians, researchers, academic centers and biopharma companies, with an initial focus on oncology. Its offerings include MI Profile, which analyzes tumor tissue; Caris Assure, which analyzes blood for therapy selection and is also being developed for minimal residual disease tracking and treatment monitoring; and Precision Whole Genome, a blood- and tissue-based profiling platform. MI Profile includes the MI Cancer Seek assay, immunohistochemical testing and, in some cases, AI-based molecular signatures such as GPSai and FOLFIRSTai. Caris also uses its molecular and clinical datasets, AI and bioinformatics services in research and drug-target discovery, and partners with biopharma companies on drug development and companion diagnostics. It provides profiling services to clinical customers and data, research and testing services to industry and academic partners. Caris is headquartered in Irving, Texas.

AlphAI earnings readThird Quarter 2026 · NOV 4Caris Life Sciences Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue GuidanceVerdict: mixed

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

1
0
0

No SEC Form 4 filings for $CAI in the last 30 days.

See all $CAI insider activity →
Med

Why is Caris Life Sciences stock rallying today?

Caris Life Sciences (CRIS) stock rose 6.6% in pre-market trading, bouncing from its 200-day moving average near $21.68. The company reported Q3 2026 revenue of $275.4M, up 27% YoY, and EPS of $0.05, beating estimates. Analysts raised price targets, with an average of $31.18. The Nasdaq Composite is also higher, supporting healthcare stocks.

CAI sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning CAI (Caris Life Sciences, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.

Recent CAI coverage spans financial news, earnings and market movers.

What's driving CAI

  • Technical bounce off the 200-day moving average is reinforced by a fresh earnings narrative (revenue/EPS beat plus raised guidance), supporting near-term upside bias.

    investing.com · Nov 17, 2026

  • Piper Sandler kept its Neutral rating on Caris Life Sciences but raised its price target to $25 from $22, suggesting a 2.2% downside from the last close. Other recent analyst targets for the company range from $30 to $38.

    tradingview.com · Nov 10, 2026

  • Citigroup kept its Buy rating on Caris Life Sciences and increased its price target to $36 from $28, suggesting a 42.7% upside from the Nov 6 close of $25.23. Recent analyst price targets for the company range from $30 to $38.

    tradingview.com · Nov 6, 2026

  • TD Cowen kept its Buy rating on Caris Life Sciences and increased its price target to $38 from $36, suggesting a 14.4% upside from the Nov 4 close of $33.22. Recent analyst price targets for the company range from $30 to $38.

    tradingview.com · Nov 5, 2026

  • Positive earnings beat and raised guidance suggest upside potential.

    SEC EDGAR 8-K · Nov 4, 2026

AlphAI scores every news story that mentions CAI with an AI model for sentiment and relevance, and aggregates insider trades from Caris Life Sciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $CAI

Score

Why is Caris Life Sciences stock rallying today?

Caris Life Sciences (CRIS) stock rose 6.6% in pre-market trading, bouncing from its 200-day moving average near $21.68. The company reported Q3 2026 revenue of $275.4M, up 27% YoY, and EPS of $0.05, beating estimates. Analysts raised price targets, with an average of $31.18. The Nasdaq Composite is also higher, supporting healthcare stocks.

$CAIHighEarnings

Caris Life Sciences Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

Caris Life Sciences, Inc. (CAI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Caris Life Sciences Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance Revenue growth of 27% driven by strong performance in molecular profiling services, including approximately 61,500 clinical cases, consisting of over 358,000 total on

CAI Maintained by JP Morgan -- Price Target Raised to $35

JP Morgan maintained an Overweight rating for Caris Life Sciences Inc (CAI) and raised its price target to $35 from $25, citing confidence in the company's future performance. CAI's P/E ratio is 81.33x, higher than its 5-year median, and its GF Score™ is 11/100, indicating areas for improvement. Insider activity shows significant selling. CAI specializes in molecular science and technology, focusing on precision medicine in oncology.

Related tickers